- two routes
VYZULTA®: One active molecule, two routes1†
- Intraocular pressure (IOP) is a major modifiable risk factor for glaucoma progression
- Reduction of IOP reduces risk of glaucomatous visual field loss
- VYZULTA® is thought to lower IOP by increasing outflow of aqueous humorthrough both uveoscleral and trabecular meshwork routes†
VYZULTA® is not indicated to reduce the risk of glaucoma progression or glaucomatous visual field loss.
† Clinical significance unknown.